Decera Clinical Education Oncology Podcast

In this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R)  myelodysplastic syndromes (MDS) with a focus on the nursing perspective. Topics include:Current and ongoing clinical trials in the higher-risk and R/R MDS settingTherapies surrounding transplantNursing considerations for managing a patient with higher risk and/or R/R MDSPresenters:Sarah Tinsley, PhD, APRN, AOCNNurse PractitionerCourtesy Assistant ProfessorDepartment of Malignant HematologyMoffitt Cancer CenterUniversity of South FloridaTampa, Florida Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:Transitioning from second- to third-line therapyFactors in selecting among available therapiesKey predictors of improved outcomes with regorafenib vs TAS-102Presenters:Chiara Cremolini, MD, PhDMedical Oncologist  Unit of Medical Oncology 2  Azienda Ospedaliero-Universitaria PisanaProfessorDepartment of Translational Research and New Technologies in Medicine and SurgeryUniversity of PisaPisa, Italy Teresa Macarulla, MD, PhDMedical OncologistHead, Gastrointestinal and Endocrine Tumors Unit  Division of Medical OncologyVall d´Hebrón Institute of OncologyBarcelona, SpainContent based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Follow along with the slideset:https://bit.ly/3FjekMoLink to full program:https://bit.ly/33yrIyh Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:Atezolizumab plus bevacizumab as the current standard of careContraindications to atezolizumab plus bevacizumabThe current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinomaOngoing clinical trials in the first-line settingPresenters:  Josep M. Llovet, MD, PhD, FAASLDProfessor of MedicineDirector, Mount Sinai Liver Cancer ProgramDivision of Liver DiseasesMount Sinai School of MedicineNew York, NYProfessor of ResearchLiver Unit, IDIBAPSHospital Clinic BarcelonaBarcelona, SpainUniv. Prof. Markus Peck-Radosavljevic, MD, MBAProfessor of Medicine, Medical University of ViennaVienna, AustriaDepartment Chair, Innere Medizin and GastroenterologieKlinikum Klagenfurt am WörtherseeKlagenfurt am Wörthersee, AustriaLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,  Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancerUpdate from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancerResults from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancerPresenters:Nicole Concin, MD, PhDProfessorDepartment of Gynaecology and ObstetricsMedical University InnsbruckInnsbruck, AustriaConsultant in Gynaecological OncologyDepartment of Gynaecology and Gynaecologocial OncologyKEM Evang. Kliniken Essen-MitteEssen, GermanyContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/30PjPnl Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimensSecond-line therapeutic options after disease progression on an immunotherapy-based regimenImmunotherapy in patients with advanced NSCLC and brain metastasesDistinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsyFuture directions in immunotherapy for NSCLC, including the role of the gut microbiome in responsePresenters:Julie Brahmer, MD, MScProfessor of OncologyDirector, Thoracic OncologyCo-Director, Upper Aerodigestive Cancer ProgramBloomberg-Kimmel Institute for Cancer ImmunologySidney Kimmel Comprehensive Cancer CenterJohns Hopkins MedicineBaltimore, MarylandJarushka Naidoo, MB BCH BAO, MHSConsultant Medical OncologistBeaumont Hospital/RCSI University of Health SciencesDublin, IrelandAdjunct Assistant Professor of OncologySidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandContent based on an online CME program supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Helsinn Healthcare SA; and Merck Sharp & Dohme Corp.Follow along with the PDF:https://bit.ly/31aRRmdLink to full program:https://bit.ly/3CLC0Hd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:Mechanisms of acquired resistance to TRK inhibitor therapyClinical trial data on the second-generation inhibitors selitrectinib and repotrectinibSafety profiles of first- vs second-generation TRK inhibitorsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program, including downloadable slides:https://bit.ly/2YFIPfr Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.Presenters:Jean-Yves Blay, MD, PhDProfessor of Medical OncologyDepartment of MedicineCentre Leon BerardLyon, FranceRobin L. Jones, BSc, MBBS, MRCP, MD(Res)ProfessorSarcoma UnitRoyal Marsden Hospital and Institute of Cancer ResearchLondon, United KingdomLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:Importance of germline and somatic testingAdverse events associated with PARP inhibitorsMaintenance therapy in pancreatic cancerPresenters:Philip Agop Philip, MD, PhD, FRCPProfessorSchool of MedicineWayne State UniversityLeader, Gastrointestinal Multidisciplinary TeamDepartment of OncologyKarmanos Cancer InstituteDetroit, MichiganElena Gabriela Chiorean, MDProfessor of MedicineDivision of Medical OncologyDepartment of MedicineUniversity of WashingtonMemberFred Hutchinson Cancer ResearchSeattle, WashingtonContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program:https://bit.ly/3jEehCcLink to associated downloadable PDF:https://bit.ly/3nSfTcR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:Individualizing therapyClinical data and experience informing optimal dosingKey adverse eventsPresenters:Kanwal Raghav, MD, MBBSAssociate Professor, Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer CenterHouston, TexasRachel Riechelmann, MD, PhDHead, Clinical Oncology DepartmentMedical OncologistAC Camargo Cancer Center Sao Paulo, Brazil Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Link to full program: https://bit.ly/3aVXplL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:Basket trials leading to FDA approvals of larotrectinib and entrectinibCurrent pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLCSequencing treatment with TRK inhibition in patients with solid tumorsClinically relevant similarities and differences between larotrectinib and entrectinibPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program, including downloadable slidesets:https://bit.ly/2YFIPfr Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.